Patients still come in today asking for the 3 tests for liver fibrosis, which are actually outdated. The WHO recommends two non-invasive tests to rate the staging of liver disease to assist in determining who needs to be treated. One is based on a blood test APRI score and the other is a transient elastography, FibroScan. After years of research, if the APRI score is >2, it predicts that the patient has developed cirrhosis. For example, the test report of a male hepatitis B patient shows AST 80 U/L (normal reference range: 0-40 U/L) and platelets 95×109/L, then his APRI score is: What is cirrhosis, decreased albumin, enlarged spleen and decreased platelets is typical cirrhosis, even if no liver disease was previously detected. When a patient with hepatitis B and C has reduced platelets, he should be suspected of having cirrhosis, which can be calculated using the above formula.